JP Morgan Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $27
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Brian Cheng has maintained an Overweight rating on ITeos Therapeutics (NASDAQ:ITOS) but has lowered the price target from $29 to $27.

March 12, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan maintains an Overweight rating on ITeos Therapeutics but lowers the price target from $29 to $27.
While the reduction in price target might suggest a slightly less optimistic outlook, the maintenance of an Overweight rating indicates continued confidence in the company's fundamentals. This mixed signal could lead to neutral short-term price movement as investors digest both the positive and negative aspects of the analyst's view.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100